Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
Thymalin Thymic epithelial stimulation, increases CD4+/CD8+ differentiation 5–10mg SC twice weekly for 10–20 days CD4+ count increase 12–28%, thymulin levels normalize within 4 weeks Gold standard for T-cell restoration in viral …
Follistatin Binds activin to enhance FSH receptor sensitivity in granulosa cells Diminished ovarian reserve, poor responder protocols 1–3 mg/kg subcutaneously during early follicular phase Subcutaneous injection Promising for DOR…
Reduced L-Glutathione (GSH) Direct thiol-mediated binding; GST-catalysed conjugation; biliary and renal excretion Mercury, lead, cadmium, arsenic (divalent metals) 500–1000mg twice daily (oral); 600–1200mg IV (clinical chelation …
Thymalin T-regulatory cell differentiation, IL-10/TGF-beta upregulation Immune dysregulation, chronic inflammation, Th17 dominance 5–10mg SC 2–3×/week, 8–12 weeks Human RCTs in autoimmune conditions; reduced IL-17 40–55% Stronges…
Thymalin Thymic T-cell restoration via thymulin receptor activation Moderate (Phase 2–3 trials in immune restoration; observational data in herpesvirus contexts) 5–10mg subcutaneous every 48–72 hours × 14–28 days 30–40% reduction…
| Compound | Primary Mechanism | HPG Axis Impact | Typical Research Dose | Time to Measurable Effect | Recovery After Cessation | Professional Assessment ||—|—|—|—|—|—|| Gonadorelin | GnRH receptor agonist. Stimulates LH/FSH rele…
CJC-1295 + Ipamorelin Dual-pathway GH secretagogue. Pulsatile release preserves physiological rhythm Small Phase 2 trials show improved oocyte yield in poor responders; no large RCTs 200–250 mcg each peptide subcutaneously before…
Thymalin Thymic epithelial growth factor upregulation → T-cell differentiation Bone marrow, thymus, lymphoid tissue 24–72 hours (optimal); effective up to 7 days Strong. Multiple controlled animal studies; Russian clinical data i…
Thymalin T-cell modulation, cytokine regulation Reduces inflammation-driven cortisol demand through immune normalization Russian gerontology studies; aged rodent models; no randomized human cortisol trials 5–10mg subcutaneous, 2–…
Thymalin Restores thymic epithelial function and T-cell differentiation Thymus, immune system 10mg SC daily × 10 days 4–6 weeks for normalised CD4/CD8 First-line for immune dysregulation. Addresses root cause of autoimmune-like s…
Thymalin Thymic peptide signalling, T-cell regulation Immune-dominant (elevated cytokines, NK cell dysfunction) 2–3x weekly subcutaneous Moderate (published cytokine normalisation data in post-viral fatigue) Best first-line choic…
Understanding the distinct mechanisms, administration routes, and evidence bases for the best peptides for adrenal support allows researchers to select compounds that align with specific physiological targets. Thymalin Modulates …
Thymalin Thymic immune modulation. Restores T-regulatory cell function to reduce ovarian inflammation Immune rebalancing in follicular microenvironment 5–10mg/week subcutaneous Injection (reconstituted) Preclinical models; human …
Thymalin Thymic epithelial cell activation → T-cell maturation and thymulin secretion Immunosenescence and declining adaptive immunity 5–10mg subcutaneous, 10-day cycles Subcutaneous injection after reconstitution in bacteriostat…
Thymosin Alpha-1 TLR9 agonist; upregulates IL-2 and IFN-gamma via dendritic cell activation Increased CD4+ counts (18–22% in HBV trials); enhanced cytotoxic T-cell differentiation Phase III HBV trials (Hepatology 2004); chronic v…
Understanding which peptide fits which aging mechanism requires side-by-side comparison of targets, bioavailability, and evidence quality. P21 CREB pathway activation → synaptic protein synthesis without BDNF dependence Subcutane…
L-Carnosine (dipeptide) Direct antioxidant + metal chelation DNA fragmentation index (DFI) Human trials show 20–25% DFI reduction in OAT patients Strong mechanistic rationale; safest option with clinical evidence MOTS-c Mitochond…
The table below compares the three peptides with the strongest preclinical evidence for influencing internal scar tissue, organized by mechanism, dosing range, and tissue-type suitability. BPC-157 VEGF upregulation, TGF-β downreg…
| Peptide | Primary Mechanism | Target Cell Type | Clinical Evidence | Typical Dosing Protocol | Time to Sperm Detection | Professional Assessment ||—|—|—|—|—|—|| Human Chorionic Gonadotropin (hCG) | Mimics LH; stimulates Leydig …
Before selecting peptides, understand the distinct recovery phases they target and the evidence quality supporting each. Thymalin Thymic epithelial stimulation → T-cell maturation Immune reconstitution (weeks 4–12 post-chemo) Pha…